Antipsychotic prescribing in care homes before and after launch of a national dementia strategy: an observational study in English institutions over a 4-year period

Ala Szczepura,1 Deidre Wild,1 Amir J Khan,1 David W Owen,2 Thomas Palmer,3 Tariq Muhammad,4 Michael D Clark,5 Clive Bowman6

ABSTRACT

Objectives: To assess associations between the launch of the National Dementia Strategy (NDS) and antipsychotic prescribing in long-term residential care (LTC) in England.

Setting and participants: Retrospective analysis of prescribing patterns in 616 LTC institutions (31 619 residents) following launch of the NDS, using information from electronic medicines management system.

Primary and secondary outcome measures: Antipsychotic prescribing point prevalence (PP) for all residents in a cross section of LTC settings over a 4-year period following NDS launch. Secondary outcomes included dosages, length of treatment and use of recommended second-generation antipsychotics (SGAs) versus first-generation antipsychotics (FGAs). Associations between facility-level PP values and institutional characteristics, resident demographics were explored. Variations across geographical areas examined. Prescription net ingredient costs calculated.

Results: No statistically significant difference was observed in overall prescribing rates over the 4-year period (Kolmogorov-Smirnov (KS) test p=0.60), and there was no significant shift towards newer SGAs (KS test p=0.32). Dosages were above the maximum indicated in only 1.3% of cases, but duration of prescribing was excessive in 69.7% of cases. Care homes in the highest prescribing quintile were more likely to be located in a deprived area (rate ratio (Q5/ Q1) RR=5.89, 95% CI 4.35 to 7.99), registered for dementia (RR=3.38, 95% CI 3.06 to 3.73) and those in the lowest quintile were more likely to be served by a single general practitioner (GP) practice (RR=0.48; 95% CI 0.37 to 0.63); p<0.001 all. A sixfold variation observed in overall prescribing rates over the 4-year period. Variations in PP levels were explored. Variations across geographical areas examined. Prescription net ingredient costs calculated.

Conclusions: The NDS in England was not associated with reduced PP levels or the types of antipsychotic prescribing in care homes. Further research is needed to explore why. Clear standards specifying recommended agents, dosages and length of treatment, together with routine monitoring and greater accountability for antipsychotic prescribing, may be required.

INTRODUCTION

There continues to be considerable international debate about the optimum care of older people with dementia, especially those living in care homes.1–4 In England, it is estimated that 46% of new admissions to care homes are for reasons of dementia5 and more than one-third of people with dementia (36.5%) now live in care homes.6 For antipsychotics, which were originally developed for use in patients with schizophrenia or psychosis, there is evidence of ‘off-label’ prescribing of unlicensed medicines for behavioural and psychological symptoms in dementia (BPSD).6–7

Strengths and limitations of this study

To our knowledge, this is the first UK study to examine long-term impact of a national policy initiative on antipsychotic prescribing in care homes. The samples studied are many times those of other UK antipsychotic usage studies.

Prescribing rates, antipsychotic agent type (including unlicensed antipsychotics) and length of treatment were unchanged.

The factors preventing sustained change in antipsychotic prescribing and regional variations observed remain unclear.

One limitation of this observational study is the lack of comparable national data to demonstrate representativeness of the study sample.

A further limitation of this study is the lack of clinical and staffing data to complement the detailed prescription data.

For numbered affiliations see end of article.
In the 1990s, calls in the USA for control of the use of first-generation antipsychotics (FGA) for BPSD led to the Omnibus Budget Reconciliation Act (OBRA) which introduced regulation stipulating recommended dosages for their use in nursing homes.3–9 In the UK, thioridazine (trade name Melleril), a commonly used FGA, was banned in 2008 following evidence of cardiac toxicity and limited effectiveness.10 Prior to its ban, thioridazine was the most commonly prescribed antipsychotic in UK long-term residential care (LTC), accounting for 51–74% of prescriptions.31, 12 With the introduction of second-generation antipsychotics (SGAs),13 concerns continued to be raised in the UK and the USA about their use for BPSD treatment.14 15 In the USA, no antipsychotic has been approved to date by the Food and Drug Administration for BPSD.16 In the UK, the Medicines & Healthcare products Regulatory Agency has licensed only one antipsychotic (risperidone), for short-term BPSD treatment (up to 6 weeks) and for persistent aggression.17 Australia and Canada have similarly only approved risperidone.18 19 In most countries, therefore, use of other antipsychotics remains unlicensed or off-label.20 It has recently been argued that widespread off-label prescribing for BPSD requires regulatory intervention to safeguard vulnerable older people.21

Inappropriate prescribing of antipsychotic medication is recognised as a marker of poor care,3–22 especially if prescriptions are not regularly reviewed by the prescribing physician.23 Although the principle of protecting older people’s human rights when they cannot consent to treatment is well developed with respect to the use of physical restraints and deprivation of liberty, it is acknowledged that protection against inappropriate use of ‘chemical restraints’ is less well developed.24 To date, controlled trials have demonstrated limited clinical efficacy for use of antipsychotics in BPSD, with only small effect sizes reported on global behavioural disturbance.25 Long-term use of antipsychotic drugs is also associated with increasing concerns about serious adverse effects including mortality.26 The European Federation of Neurological Societies task force recommended in 2007 that all antipsychotics be used with caution in elderly patients with dementia, although no specific guidance was provided on dosage or length of treatment.27

In 2009, the UK Department of Health commissioned a policy review on antipsychotic use in dementia. The resulting report concluded that usage was unacceptably high and recommended a two-thirds reduction over a period of 3 years as a target.20 The UK Royal College of Psychiatrists confirmed that older people could safely be withdrawn from agents like risperidone over a 2–4-week period with no adverse consequences.28 29 This policy review also stipulated that SGA agents should be prescribed in preference to FGA agents; that the lowest possible effective dose should be prescribed for the shortest period (ideally <12 weeks); and that treatment should be reviewed at least monthly with reduction or cessation actively considered at each review.20 Similar recommendations were incorporated as guidelines in a National Dementia Strategy (NDS) launched in February 2009.30 31

In England, the majority of care home residents (60%) are in residential homes typically with no on-site nursing staff.32 33 Although general practitioners (GPs) prescribe and are responsible for monitoring medication in care homes, medicines management (ordering, administering) is undertaken by social care staff who may have no formal training in medication practice.34 In the USA, administration of antipsychotic treatment by untrained staff unaware of safety issues is reported to have been a contributory pressure leading to the OBRA initiative. In this paper, we report the findings of a large-scale study in England that examines antipsychotic prescribing in nursing and residential homes following the introduction of the NDS. To date, the UK research on medication use in care homes remains limited,35–37 with no large-scale studies of antipsychotic prescribing levels generally or long-term impact of the NDS. Our research investigated whether prescribing levels changed over the 4 years following introduction of the NDS guidance; the degree to which recommendations in terms of the types of agents prescribed and the length of treatment have been achieved; and variations in the patterns of prescribing between different institutions and geographical areas.

OBJECTIVES

- To assess whether the implementation of the NDS was associated with a decrease in prescribing of antipsychotics in LTC and, where prescribed, a shift towards newer SGAs.
- To examine differences in prescribing patterns between LTC institutions and different geographical areas, including the agents prescribed, dosages and length of exposure (LOE).
- To explore the characteristics of high/low prescribing LTC institutions.
- To consider the potential use of data on prescribing in UK LTC.

METHODS

Overview and data preparation

Prescription data were provided via a double-barcode electronic medicines management (EMM) system designed for care homes (see online supplementary file 1). This source had previously been used to examine drug administration patterns in care homes (see online supplementary file 2).35 Data were downloaded by the company for all care homes with the EMM system for the period 2009–2012, downloaded in two separate anonymised files and merged for analysis. The first contained details of all antipsychotic prescriptions, and the second de-identified resident data and anonymised LTC
characteristics. Data were analysed at two time points: 1 January 2009 (prior to NDS launch) and 31 December 2012 (4 years post-NDS). For each time point, a complete data set was examined to include all residents, there were no exclusions. Because the number of care homes which had implemented the EMM system increased over this period, a data subset was extracted for a cohort of care homes with the EMM system in place throughout the 4-year period (Cohort C). The National Research Ethics Service, National Patient Safety Agency, London W1T 5HD approved this retrospective study, which was designated a service evaluation (reference number 04/02 28 October 2009).

For each prescription, dosage was converted to an equivalent daily dose in milligram; administration format was classified as tablet, liquid or injection; trade names were recoded to a common single British National Formulary (BNF) name. All non-risperidone use was defined as off-label. Care homes were characterised in terms of following: type of institution (eg, nursing, residential home); registration status (eg, registered for ‘dementia’ or ‘old age only’); number of beds; any self-declared specialism (eg, Alzheimer’s care); and geographical location.

Dosages were compared with an ‘indicative’ maximum daily dosage (IDD), predefined for each agent. Three different sources were used in turn, since there is no comprehensive UK guidance on IDD levels for older people. First, if the BNF contained a recommended dose for ‘agitation and restlessness’ in older people or less specifically for ‘elderly patients’ this was used as ‘best available’ evidence. Second, if the US OBRA recommendations specified a maximum dosage, this was used. Finally, for all other agents the upper dosage reported in a UK survey of hospital specialists in old age psychiatry for dementia was used. The LOE was estimated by summing repeat antipsychotic prescriptions for each individual resident until the final prescription; due to the time-consuming nature of this process, such analysis was limited to the licensed agent (risperidone).

Net ingredient cost of each antipsychotic prescription, excluding any dispensing costs or fees, was estimated using BNF unit prices (accessed 6 December 2012).

Primary medical support was categorised in terms of the number of GP practices, serving an LTC facility plus the size of these practices (ie, number of doctors). An additional proxy measure of quality was whether these included a teaching practice.

LTC neighbourhoods were classified as ‘deprived’ or ‘non-deprived’, with deprived defined as a neighbourhood in the top 10% of Index of Multiple Deprivation scores nationally.

Each LTC was linked to the body responsible for health services in its geographical area (ie, Primary Care Trusts (PCTs) at this time); PCTs were coterminous with local government authorities responsible for provision of LTC social care services.

Statistical analysis
A comparative descriptive design was adopted comparing cross-sectional and longitudinal data. Numerical data were summarised using mean and SD or median and range depending on data distribution. Stata (V.12) was used for all analyses.

Sample descriptors and prescribing patterns
Prescribing patterns were analysed to include PP levels for all antipsychotics and for FGA / SGA separately, dosages in terms of IDD levels and LOE for risperidone. The mean annual expenditure on antipsychotics per resident was estimated by summing the cost of all prescriptions in an LTC setting and dividing by the total number of residents; costs were adjusted to 2012 prices.

Trend in prescribing
Cumulative distribution plots of PP values were produced for all antipsychotics and separately for FGA and SGA agents. The two-sample Kolmogorov-Smirnov non-parametric statistical test (KSS2-test) was used to compare distributions at baseline and 48 months. Plots for the common subset (Cohort C) were similarly compared.

Characteristics of high/low prescribing institutions
Care homes were placed into quintiles based on their baseline PP level; if an organisation was placed in a particular quintile, all residents in that home were placed in the same quintile. Quintiles were compared for categorical variables (ie, resident demographics and care home characteristics). Rate ratios were derived for the fifth quintile divided by the first quintile and 95% CI limits reported using a δ-method SE.

Geographical variations
For each PCT area, the mean prescribing level (PP value across all care homes), ratio of SGA:FGA prescriptions and the proportion of off-label (ie, non-risperidone) prescriptions were estimated. For risperidone, the
proportion of cases in which this was the first-line therapy was calculated, together with PP values for risperidone.

RESULTS
Sample descriptors
Table 1 shows details of baseline and 48-month samples. The mean age of residents was 83.7 years (baseline) and 78.8 years (48 months), and the majority were female (71.9% vs 68.0%). Cohort C demonstrated a similar age/gender breakdown. At baseline, 55% of care homes operated in a ‘multipractice’ context (served by ≥4 GP practices), with only 13.7% served by a single GP practice; 24% had access to at least one teaching GP practice. Number of GP practices was not related to care home size, so in the multipractice model individual GP practices were caring for 3–13 residents versus 30–41 patients in the single practice model. A total of 48% of care homes were registered for dementia and the remainder for ‘old age only’.

Pattern of antipsychotic agents prescribed
Table 2 provides a detailed breakdown of antipsychotic prescribing over the 48-month period. This shows that mean PP rates did not reduce significantly; 18% at baseline versus 19% at 48 months post-NDS. Further analysis indicates that nursing and residential homes exhibit similar PP rates; 17.3% and 18.6%, respectively, at baseline, and 21.0% and 19.2%, respectively, at 48 months. SGAs are the most frequently used agents (68% of all prescriptions), as recommended in the NDS, with no significant differences between nursing and residential homes. Similar patterns are observed in Cohort C. FGA agents are prescribed less often than SGAs, with haloperidol the most commonly used. Although six residents were still prescribed the banned FGA thioridazine at baseline, by 2012 this figure had fallen to zero.

Residents were very rarely (0.7% at baseline and 1.6%, respectively) prescribed more than one antipsychotic at the same time. Most antipsychotics were administered in tablet form (82%) with 17% as an oral liquid. The average annual expenditure on antipsychotics was £65.6 per person resident (2012 prices). Expenditure was slightly higher in nursing homes (£71.0) than residential homes (£60.4).

The vast majority of treatments at baseline (82%) were above the recommended 6 weeks; at the end of 2012, this figure had risen to 87.3%, with 69.7% and 77.6%, respectively, above 12 weeks. In contrast, dosages were within IDD levels in 98.7% of cases at baseline; PRN prescriptions were extremely rare (<1%).

Table 1 Care home and resident characteristics

| Sample characteristics | Total (Baseline (1 January 2009)) | Month 48 (31 December 2012) | Cohort C (Baseline (1 January 2009)) | Month 48 (31 December 2012) |
|------------------------|----------------------------------|-----------------------------|----------------------------------|-----------------------------|
| Number of homes        | 211                              | 616                         | 166                              | 166                         |
| Number of residents    | 8357                             | 31 619                      | 6979                             | 9006                        |
| **Resident demographics** |                                  |                              |                                  |                              |
| Women, %               | 71.9                             | 68.0                        | 71.9                             | 69.1                        |
| Age years (mean)       | 83.7                             | 78.8                        | 83.8                             | 80.1                        |
| 65–74 years, %         | 8.9                              | 16.9                        | 8.8                              | 14.4                        |
| 75–84 years, %         | 34.8                             | 44.5                        | 34.8                             | 45.5                        |
| 85 years and over, %   | 52.5                             | 30.3                        | 52.8                             | 34.0                        |
| **Care home characteristics** |                                  |                              |                                  |                              |
| Mean size (number of residents) | 39.6                            | 51.3                        | 42.0                             | 54.3                        |
| Median size (IQR)      | 37 (18)                          | 46 (30)                     | 39 (19)                          | 49 (28)                     |
| Type of home (% all homes) |                                  |                              |                                  |                              |
| Residential home, %    | 47.9                             | 25.8                        | 48.8                             | 48.2                        |
| Nursing home, %        | 39.3                             | 23.5                        | 39.2                             | 34.9                        |
| Dual registered* %     | 12.8                             | 50.7                        | 12.1                             | 16.9                        |
| Medical support (% all homes) |                                |                              |                                  |                              |
| 1 GP practice, %       | 13.7                             | 11.0                        | 11.5                             | 8.4                         |
| 2–3 GP practices, %    | 31.3                             | 29.7                        | 31.9                             | 29.5                        |
| 4+ GP practices, %     | 55.0                             | 59.3                        | 56.6                             | 62.1                        |

*Providing nursing and residential care.

GP, general practitioner.
Characteristics of high/low prescribing institutions

Table 3 presents the characteristics of residents and LTC institutions in the highest and lowest prescribing quintiles. In terms of care home characteristics, size and type of institution (nursing or residential) show no clear differences. However, the highest quintile is more likely to include residents in institutions situated in a deprived neighbourhood (rate ratio (Q5/Q1) RR=5.89, 95% CI 4.35 to 7.99), those in homes registered for dementia (RR=3.38, 95% CI 3.06 to 3.73), or residents in homes served by four or more GP practices (RR=1.38; 95% CI 1.30 to 1.46). In terms of resident characteristics, older residents aged 85 years plus were less likely to be in the upper quintile (RR=0.63, 95% CI 0.58 to 0.68) and younger residents aged 65–74 more likely (RR=1.75, 95% CI 1.41 to 2.17). Those aged 75–84 years have a 95% CI which does not overlap with the other two groups, suggesting they are more likely to be in the upper quintile than those aged 85 plus, but less likely than those aged 65–74. There was a slight gender difference (females RR=0.86, 95% CI 0.82 to 0.90).

Geographical variations

Table 4 presents PCT-level data for the 26 geographical areas in which care homes are located. PCT areas, arranged in order of decreasing PP rates, demonstrate a sixfold

---

Table 2 Breakdown of antipsychotic prescribing patterns

| Prescribing | Total Baseline (1 January 2009) | Month 48 (31 December 2012) | Cohort C Baseline (1 January 2009) | Month 48 (31 December 2012) |
|-------------|-------------------------------|-----------------------------|----------------------------------|-----------------------------|
| PP, %       |                               |                             |                                  |                             |
| All antipsychotics | 18.0 (±12.0) | 19.0 (±15.2) | 18.3 (±11.9) | 18.0 (±12.3) |
| Median (IQR) | 15.2 (11.8) | 15.4 (14.0) | 15.3 (11.4) | 15.1 (12.7) |
| SGAs        |                               |                             |                                  |                             |
| All SGAs    | 12.5                          | 14.6                        | 12.8                             | 13.9                        |
| Quetiapine  | 5.1                           | 4.7                         | 4.9                              | 3.9                         |
| Risperidone | 4.0                           | 5.3                         | 4.2                              | 6.4                         |
| Olanzapine  | 2.1                           | 3.0                         | 2.3                              | 2.9                         |
| FGAs        |                               |                             |                                  |                             |
| All FGAs    | 5.9                           | 5.4                         | 5.8                              | 5.2                         |
| Haloperidol | 2.5                           | 3.0                         | 2.3                              | 2.4                         |

**Daily dosage, %**

- Recommended: 98.7, 98.6
- High: 0.3, 0.3
- Excessive: 1.0, 1.1

**Length of exposure, %**

- Recommended: 18.0, 18.2
- Acceptable: 12.3, 12.2
- Excessive: 69.7, 69.7

*Percentage of total prescriptions with following daily dosage: ‘recommended’ ≤ maximum IDD; ‘high’ >100–200% IDD; ‘excessive’ >200% IDD.
†Percentage of risperidone prescriptions with following LOE: ‘recommended’ ≤6 weeks; ‘acceptable’ >6 to <12 weeks; ‘excessive’ ≥12 weeks.

FGAs, first-generation antipsychotics; IDD, indicative maximum daily dosage; LOE, length of exposure; NA, not applicable; PP, point prevalence; SGAs, second-generation antipsychotics.

---

Figure 1 Cumulative distribution plots of prescribing point prevalence values care homes at 1 January 2009 (baseline) and 31 December 2012 (48 months) for all antipsychotics.
variation in prescribing level between 5.7% and 37.5% (overall mean 17.6%). The proportion of prescriptions for SGAs similarly shows an eightfold difference, ranging between 11.1% and 89.5% (mean 62.9%), with SGA use unrelated to overall PP value. Rates of off-label (non-risperidone) prescribing vary between 5.4% and 31.3% (mean 13.9%). For risperidone, an overall PP value of 3.7% masks large geographical differences (range 0–6.2%). Detailed analysis of risperidone prescriptions also indicates that, although this was the first-line treatment in 75.2% of cases when prescribed, this figure varies between 0% and 100% in individual PCTs as shown in the final column.

**DISCUSSION**

This study has used data on many more care home residents than any similar UK study. This shows that reductions in the prescribing of antipsychotics driven by the NDS have not been sustained in care homes. Furthermore, we demonstrate that contrary to guidance, older antipsychotic agents are still being used extensively rather than safer SGAs. We observed that most residents were prescribed antipsychotics within acceptable dosages; however, in the majority of cases, length of treatment was excessive. These results differ from an analysis of UK GP practice records over 16 years which identified a fall in levels of prescribing of antipsychotics at the point when dementia is first recorded, from 19.9% in 1995 to 7.4% in 2011.

A recent study in England found that the launch of the NDS was linked to an increase in diagnosis rates and prescriptions for anti-dementia medications from 2006/2007 to 2011/2012. A trend towards earlier diagnosis may explain the fall in antipsychotic prescribing reported in 2011 in the first study. Neither study provided separate figures for care homes. In the USA, differences in prescribing rates in nursing homes before and after the introduction of OBRA have been reported.

**Table 3** Care homes in high and low prescribing quintiles (baseline sample)

| Care home characteristics       | Total population | Quintile Q1 (lowest) | Quintile Q5 (highest) | RR (95% CI) Q5/Q1 |
|--------------------------------|-----------------|----------------------|-----------------------|------------------|
| Home type                      |                 |                      |                       |                  |
| Residential home—n (%)         | 3703 (44.3)     | 831 (46.3)           | 737 (51.5)            | 1.11 (1.04 to 1.19) |
| Nursing home—n (%)             | 3422 (41.0)     | 682 (38.0)           | 561 (39.2)            | 1.03 (0.95 to 1.13) |
| Dual registered—n (%)          | 1232 (14.7)     | 282 (15.7)           | 133 (9.3)             | 0.59 (0.49 to 0.72) |
| Registered for dementia        | 3359 (48.0)     | 335 (22.3)           | 913 (75.4)            | 3.38 (3.06 to 3.73) |
| Registered for old age, not dementia | 3644 (52.0) | 1168 (77.7)         | 298 (24.6)            | 0.32 (0.29 to 0.35) |
| Area deprivation               |                 |                      |                       |                  |
| Deprived neighbourhood—n (%)  | 459 (6.1)       | 48 (2.9)             | 219 (17.1)            | 5.89 (4.35 to 7.99) |
| Non-deprived neighbourhood—n (%) | 7089 (93.9) | 1598 (97.1)         | 1059 (82.9)           | 0.85 (0.83 to 0.88) |
| Practices serving home        |                 |                      |                       |                  |
| 1 GP practice—n (%)            | 866 (10.4)      | 180 (10.0)           | 68(4.8)               | 0.48 (0.37 to 0.63) |
| 2–3 GP practices—n (%)         | 3011 (36.0)     | 729 (40.6)           | 387 (27.0)            | 0.67 (0.60 to 0.74) |
| >4 GP practices—n (%)          | 4480 (53.6)     | 886 (49.4)           | 976 (68.2)            | 1.38 (1.30 to 1.46) |
| Care home size*                |                 |                      |                       |                  |
| Small—n (%)                    | 545 (6.5)       | 183 (10.2)           | 95 (6.6)              | 0.65 (0.51 to 0.82) |
| Medium—n (%)                   | 2887 (34.6)     | 554 (30.9)           | 643 (44.9)            | 1.45 (1.33 to 1.59) |
| Large—n (%)                    | 4925 (58.9)     | 1058 (58.9)          | 693 (48.5)            | 0.82 (0.77 to 0.88) |
| Age/gender of residents        |                 |                      |                       |                  |
| Women—n (%)                    | 6011 (71.8)     | 1343 (74.8)          | 922 (64.4)            | 0.86 (0.82 to 0.90) |
| Age 65–74—n (%)                | 744 (8.9)       | 129 (7.2)            | 181 (12.6)            | 1.75 (1.41 to 2.17) |
| Age 75–84—n (%)                | 2911 (34.8)     | 554 (30.9)           | 564 (39.4)            | 1.28 (1.16 to 1.40) |
| Age >85—n (%)                  | 4392 (52.5)     | 1071 (59.7)          | 536 (37.5)            | 0.63 (0.58 to 0.68) |

*p Values in the RR column are from Pearson’s χ² test of associated between the characteristic variable and the first and fifth quintile indicator. *Small ≤24 residents; medium 25–39 residents; large ≥40 residents.

GP, general practitioner; NA, not applicable; RR, Rate ratio.
single-region study among 934 residents. Elsewhere, it has been suggested that up to 27% of UK care home residents may be receiving antipsychotics. More recently, a survey of care home managers in the East of England identified a rate of 12%; this was self-reported by 299/737 managers, so response bias cannot be ruled out. Internationally, US rates appear to be slightly higher, although studies are limited to nursing homes. Rates of 27.6% in 2000–2001, 8% in 2005 and 25% in 2011 have been reported for large-scale population samples. In contrast to these US figures, which are based on 2–3 million Medicare beneficiaries, smaller scale studies in other parts of the world generally report higher levels of antipsychotic use. Rates of 27.6% in 2000–2001, 8% in 2005 and 25% in 2011 have been reported for large-scale population samples. In contrast to these US figures, which are based on 2–3 million Medicare beneficiaries, smaller scale studies in other parts of the world generally report higher levels of antipsychotic use. Reported rates in 2005–2006 include 30.3% and 36.9% in two Canadian LTC facilities, 25.1% in 40 Australian nursing homes and 39–42% in 41 institutions in Finland. The rates observed in our study are therefore comparatively low.

Although we found no decrease in overall prescribing levels, it is also important to consider why we observed no shift towards SGAs, why off-label prescribing remained high and why length of treatment continued to exceed the recommended 6–12 weeks (although dosages were within an acceptable range). A comparable 2005 analysis of data for US nursing home residents found 73.5% were receiving SGAs, 13.4% FGAs and 13.0% both. In our study, the proportion of SGAs was similar at 69%, but <2% residents were prescribed more than one agent. In Australia, a much lower level (40%) of SGA use has been reported in a cohort study of 2005 residents. In our baseline cohort, the most commonly prescribed SGAs were quetiapine, risperidone and olanzapine. This is similar to self-reported preferences in a survey of UK hospital specialists in old age psychiatry. In terms of dosage levels, there is no other recent UK evidence available. However, a US study found that 17.2% of 1096 nursing home residents were prescribed antipsychotic doses (excluding PRN) that exceeded maximum levels. Our study indicates a lower level of 1.3% in England. Our findings also confirm that off-label prescribing continues to be a problem. In March 2012, the US Centers for Medicare and Medicaid Services launched a quality initiative that recommended a 15% decrease in off-label prescribing of unlicensed antipsychotics in nursing homes over 9 months. No similar quality initiative has been launched in the UK.

### Table 4 Prescribing patterns by geographical area (baseline sample)

| PCT area | Antipsychotic prescriptions | Risperidone prescriptions |
|----------|----------------------------|---------------------------|
|          | Point prevalence all (%)   | Point prevalence (%)      |
|          | Proportion SGA agents (%)  | Percentage which are      |
|          |                            | first-line prescriptions   |
|          |                            |                           |
| Area 1   | 37.5                       | 6.2                       |
| Area 2   | 24.8                       | 2.1                       |
| Area 3   | 24.3                       | 2.7                       |
| Area 4   | 24.1                       | 4.1                       |
| Area 5   | 23.5                       | 2.5                       |
| Area 6   | 22.0                       | 6.0                       |
| Area 7   | 20.9                       | 1.7                       |
| Area 8   | 20.6                       | 2.4                       |
| Area 9   | 19.9                       | 6.1                       |
| Area 10  | 19.2                       | 0.5                       |
| Area 11  | 17.6                       | 5.2                       |
| Area 12  | 17.5                       | 0                         |
| Area 13  | 17.3                       | 1.4                       |
| Area 14  | 17.0                       | 3.6                       |
| Area 15  | 15.6                       | 2.2                       |
| Area 16  | 15.5                       | 1.0                       |
| Area 17  | 15.1                       | 4.9                       |
| Area 18  | 15.1                       | 0                         |
| Area 19  | 14.3                       | 0.9                       |
| Area 20  | 14.1                       | 0.7                       |
| Area 21  | 13.4                       | 2.1                       |
| Area 22  | 13.2                       | 2.6                       |
| Area 23  | 11.8                       | 1.3                       |
| Area 24  | 10.8                       | 5.4                       |
| Area 25  | 8.7                        | 5.4                       |
| Area 26  | 5.7                        | 0                         |
| Total    | 17.6                       | 3.7                       |

NA, not applicable; PCT, Primary Care Trust; SGA, second-generation antipsychotic.
The key drivers influencing excessive treatment length are unclear. No data are published on who initiates antipsychotic treatment in LTC in England (eg, hospital clinicians or GPs), although there is research on continuation of treatment. A study in one UK region found that 79% of residents in 10 care homes who were prescribed risperidone or olanzapine were under GP-only care, and monitored only infrequently.13 Similarly, a study of 65 English care homes identified infrequent monitoring with only 25% of residents who were prescribed an antipsychotic receiving a medication review by their GP in the preceding 12 months.4 More recently, a British Geriatrics Society Inquiry found that continuation of therapy is largely managed by GPs, with evidence that they may fail to undertake regular reviews as recommended.30 The excessive treatment length observed in our cohort may therefore be associated with a lack of regular review by GPs or community pharmacists. An added reason offered for continuation of antipsychotic treatment in care homes is to reduce distress of staff.57–58 Against this, there is evidence of wide variability in distress among care staff exposed to the same resident behaviour, and poor agreement among senior staff about which of their residents present with challenging behaviour.59 In fact, research from Denmark indicates that behavioural problems are a determinant for the use of antipsychotics, irrespective of the resident’s diagnosis.50

The large variations we observed in antipsychotic use between care homes may be due to various factors such as clinical need, staffing levels or broader organisational factors such as leadership and investment in staff development.60 Although we found residents in care homes registered for dementia were over-represented in our highest prescribing quintile indicating a link with clinical need, other factors appeared to have a greater impact. Since we lacked clinical data to complement the detailed prescription data, these could not be explored further. However, researchers elsewhere have identified that clinical need does not appear to be a key driver influencing prescribing rates. A Canadian study which recorded a threefold variation among 485 nursing homes found that residents were prescribed antipsychotics irrespective of clinical indication.62 Similarly, for 16,586 newly admitted nursing home residents, a US study reported that someone entering a home which exhibits the highest prescribing rate is 1.37 times more likely to receive antipsychotics, after adjusting for potential clinical indications, than someone admitted to the lowest prescribing facilities.2

‘Prescribing culture’ has therefore been suggested as an important factor influencing antipsychotic use in nursing home.2 63–66 In our study, although we could not measure prescribing culture, residents in homes served by a single GP practice were more likely to be in the lowest prescribing quintile, compared with LTC settings with more complex multipractice medical support. Treatment culture may be influenced by a more consistent message provided by one practice, with requests to continue use of antipsychotics addressed more appropriately. In the multipractice context, where up to 21 GP practices served a single care home, the lack of consistent messages may emerge, especially important in residential homes where medication is managed by non-clinical social care staff that may require more consistent advice and support.31

Interestingly, our findings also indicate that residents in care homes located in deprived neighbourhoods are significantly over-represented in the highest prescribing quintile. Although there is no other similar UK research, a US study of 17,000 care homes has identified that compared with ‘not-for-profit’ or government-owned homes, residents in ‘for-profit’ nursing homes are more likely to be prescribed antipsychotics; this finding was explained by lower nurse staffing levels.60 Evidence on a direct relationship between staffing levels and antipsychotic use is currently lacking.68 However, a measurable and sustained reduction in nursing staff burden has been reported in a double-blind, placebo-controlled randomised controlled trial (RCT) of risperidone treatment in 279 older nursing home residents with dementia.69 A more recent RCT has found that medication also reduces informal carer time by half but is not cost-effective compared with placebo when examining the primary clinical outcome of change in depressive symptoms.70 Although we did not have staffing details in our study, six homes in the sample were identified by the Care Quality Commission (CQC) as having inadequate staffing levels,71 and all were located in deprived neighbourhoods. Placing this in context, the mean annual expenditure on antipsychotics we observed was £65.60 per resident. This is 1% of the annual cost of a UK residential home place for a person with dementia (£32,241).72

Finally, very few studies have examined geographical variations in prescribing in LTC. A recent survey of US nursing homes identified a threefold geographical difference, with lower antipsychotic prescribing levels in Hawaii (12.4%) than in Louisiana (33.5%); this was based on self-reported rates so response bias cannot be excluded.63 Our study identified even larger geographical differences in off-label prescribing and similar variations in whether the licensed agent was prescribed as first-line therapy. There is no evident reason for this.

The current study presents data from a larger sample of care homes than other UK studies to date, but there are a number of limitations. First, a lack of data on care home characteristics, at a national-level, means that it is not possible to demonstrate representativeness of the sample. Because these care homes were early adopters of the EMM innovation, it could be argued that they might also be high performers in terms of resident care, leaving little room for improvement in antipsychotic prescribing levels. However, the large range we observed in antipsychotic use between care homes, and in the types of antipsychotics prescribed and lengths of treatment, would seem to contradict this hypothesis. A further limitation was the absence of electronic health records in the facilities studied, to complement the comprehensive electronic prescription data and identify all residents with a
diagnosis of dementia. However, the majority of people with dementia in the UK did not have a formal diagnosis during this period, so it would have been difficult to identify such residents confidently using routine data. The UK is not unusual, and barriers to the introduction of electronic health records in long-term care facilities are recognised internationally. Unlike the Barber et al study, a lack of clinical data precluded the use of approaches, such as multilevel modelling, to examine patient-level data (see online supplementary file 2). Finally, although there is a possibility that the NDS may have had an impact on antipsychotic use in care homes at the time of its launch with central support, our data clearly indicate that this was not sustained over time.

**Policy and research implications**

The NDS was not associated with sustained change in the use of antipsychotics in people resident in care homes. The economic burden of dementia in the UK is estimated to be £4 billion per year, more than cancer, heart disease and stroke combined. Further strategies may be required to achieve control and reduce the inappropriate use of antipsychotics in care homes. As a first step, standards specifying recommended agents, dosages and length of treatment would be helpful. Second, consideration should be given to routine reporting of patterns of prescribing for care home residents that are subject to regulatory scrutiny; the NDS did not include long-term monitoring mechanisms let alone enforcement mechanisms. Antipsychotic prescribing patterns in UK care homes are not open to public scrutiny nor routinely reported by regulatory inspection. Finally, research is needed to explore why prescribing appears to have been unaffected by the NDS.

**Acknowledgements**

The data within this study were provided with the courtesy of Invatech Health which licences the Proactive Care System (PCS).

**Contributors**

AS and DW conceived the idea for the study. TM found and imported the relevant data. AS, AK, DO and TP completed the analyses. AS, Kelly CA, Harvey RJ. Thioridazine for dementia. Cochrane Database Syst Rev 2001(4):CD000464.

**Funding**

This project was supported by an unrestricted grant from Bupa.

**Competing interests**

None declared.

**Provenance and peer review**

Not commissioned; externally peer reviewed.

**Data sharing statement**

Additional data may be available on request from the corresponding author.

**Open Access**

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

**REFERENCES**

1. McCreary J, Fox R. Antipsychotic prescribing in nursing homes. BMJ 2012;344:e1093.
2. Chen Y, Briesacher BA, Field TS, et al. Unexplained variation across US nursing homes in antipsychotic prescribing rates. Arch Intern Med 2010;170:89–95.
3. Briesacher BA, Limcango MR, Simoni-Wastila L, et al. The quality of antipsychotic drug prescribing in nursing homes. Arch Intern Med 2005;165:1280–5.
4. Aldred DP, Perry DR, Bowie P, et al. Antipsychotic prescribing patterns in care homes and relationship with dementia. Psychiatric Bulletin 2007;31:329–32.
5. Centre for Policy on Ageing. A profile of residents in Bupa care homes: results from the 2012 Bupa census. London: Centre for Policy on Ageing, 2012.
6. Alzheimer’s Society. About Dementia. 2012. http://www.alzheimers.org.uk
7. Buck JA. Psychotropic drug practice in nursing homes. J Am Geriatr Soc 1988;36:409–18.
8. Hawes C, Mor V, Phillips CD, et al. The OBRA-87 nursing home regulations and implementation of the Resident Assessment Instrument: effects on process quality. J Am Geriatr Soc 1997;45:977–85.
9. Hughes CM, Lapane KL. Administrative initiatives for reducing inappropriate prescribing of psychotropics in nursing homes: how successful have they been? Drugs Aging 2005;22:339–51.
10. Kirchner V, Kelly CA, Harvey RJ. Thioridazine for dementia. Cochrane Database Syst Rev 2001(4):CD000464.
11. McGrath AM, Jackson GA. Survey of neuroleptic prescribing in residents of nursing homes in Glasgow. BMJ 1996;312:611–2.
12. Oborne CA, Hooper R, Li KC, et al. An indicator of appropriate neuroleptic prescribing in nursing homes. Age Ageing 2002;31:435–9.
13. Malone D, Bradley P, Lindesay J. Olanzapine and risperidone prescriptions for people with dementia in care. Psychiatr Res 2007;31:459–62.
14. Lenzer J. FDA warns about using antipsychotic drugs for dementia. BMJ 2005;330:922.
15. Committee on the Safety of Medicines. Atypical Antipsychotics and Stroke. London: Medicines and Healthcare products Regulatory Agency, 2004.
16. US Food and Drug Administration (FDA). Appendix A. Tables of FDA-Approved Indications for First- and Second-Generation Antipsychotics. 2012. http://www.ncbi.nlm.nih.gov/books/NBK84656/.
17. National Institute for Health and Clinical Excellence. Dementia: supporting people with dementia and their carers in health and social care (CG42). 2006. http://www.nice.org.uk/CG42
18. Snowden J, Day S, Baker W. Why and how antipsychotic drugs are used in 40 Sydney nursing homes. Int J Geriatr Psychiatry 2005;20:1146–52.
19. Rochon PA, Anderson GM. Prescribing optimal drug therapy for older people: sending the right message: comment on “impact of FDA black box advisory on antipsychotic medication use”. Arch Intern Med 2007;170:103–6.
20. Banerjee S. The use of antipsychotic medication for people with dementia: Time for action. 2009. http://webarchive.nationalarchives.gov.uk/20130107105354/http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_108503
21. Harding R, Peel E. ‘He was like a zombie’: off-label prescription of antipsychotic drugs in dementia. Med Law Rev 2013;21:423–77.
22. Beers M, Avorn J, Soumerai SB, et al. Psychoactive medication use in intermediate-care facility residents. JAMA 1988;260:3016–20.
23. The Health Foundation, The Royal College of General Practitioners, The Royal College of Physicians, et al. Improving medication safety for people in care homes. 2011. http://www.health.org.uk/publication/making-care-safer
24. Committee on the Safety of Medicines. Thioridazine for dementia. BMJ 1988;341:51–2.
25. Denney E, Dagnan K, Insel PS. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry 2006;14:191–210.
26. Ballard C, Day S, Sharp S, et al. Neuropsychiatric symptoms in dementia: importance and treatment considerations. Int Rev Psychiatry 2008;20:396–404.
27. Waldemar G, Dubois B, Emre M, et al. Recommendations for the diagnosis and management of Alzheimer’s disease and other disorders associated with dementia: EFNS guidelines. Eur J Neurol 2007;14:e1–26.
28. Faculty of the Psychiatry of Old Age. Atypical Antipsychotics and BPSD: Prescribing guidelines for Old Age Psychiatrists. 2004. http://www.rcpsych.ac.uk/pdf/Atypicalguidance.pdf

29. Faculty of the Psychiatry of Old Age. Atypical Antipsychotics and Behavioural and Psychological Symptoms of Dementia: Prescribing Update for Old Age Psychiatrists. 2004. http://www.rcpsych.ac.uk/pdf/BPSD.pdf

30. Department of Health. Government Response to Professor Sube Banerjee’s Report on The Prescribing of Anti-Psychotic Drugs to People with Dementia. 12 November 2009. http://www.archive.nationalarchives.gov.uk/20130107105354/http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/documents/digitalasset/dh_108363.pdf

31. Department of Health. Living well with dementia: a national dementia strategy. London: Department of Health, 2009.

32. Care Quality Commission. The state of health care and adult social care in England. An overview of key themes in 2010/11. London: CQC, 2011.

33. Szczepura A, Nelson S, Wild D. Improving care in residential care homes: a literature review. Joseph Rowntree Foundation 2008. https://www.jrf.org.uk/report/improving-care-residential-care-homes-literature-review

34. Department of Health. Building a safer NHS: improving medication safety. 2010 – 2012. Chief Pharmacist Officer. London: Department of Health, 2003.

35. Szczepura A, Wild D, Nelson S. Medication administration errors for older people in long-term residential care. BMC Geriatr 2011;11:82.

36. Barber ND, Allured DP, Raynor DK, et al. Care homes’ use of medicines studied: prevalence, causes and potential harm of medication errors in care homes for older people. Qual Saf Health Care 2009;18:341–6.

37. Patterson SM, Hughes CM, Crealey G, et al. An evaluation of an adapted U.S. model of pharmaceutical care to improve psychoactive prescribing for nursing home residents in northern Ireland (Fleetwood Northern Ireland Study). J Am Geriatr Soc 2010;58:44–53.

38. BNF. British National Formulary (BNF) 63 by Joint Formulary Committee (9 Mar 2012). 2012. http://www.bnf.org/bnf/index.htm

39. Haw C, Yorston G, Stubbs J. Guidelines on antipsychotics for dementia: are we losing our minds? Psychiatric 2009;33:57–60.

40. Department for Communities and Local Government. The English Indices of Deprivation 2010. 2011. http://www.communities.gov.uk/publications/corporate/statistics/indices2010

41. Office for National Statistics. English Health Geography. 2015. http://www.ons.gov.uk/guide-method GEOGRAPHY/beginner-s-guide/geohealth/english-health-geography/index.html

42. Hospital and Community Health Services. HCBS Pay and price series 2010/11. London: Department of Health, 2011.

43. Lopes RC, Reid I, Hobson PR. The two-dimensional Kolmogorov-Smirnov test. Amsterdam, The Netherlands: XI International Workshop on Advanced Computing and Analysis Techniques in Physics Research, 2007.

44. Martinez C, Jones RW, Rietbrock S. Trends in the prevalence of antipsychotic drug use among patients with Alzheimer’s disease and other dementias including those treated with antidepressants in the community in the UK: a cohort study. BMJ Open 2013;3:pii: e002080.

45. Mukadam N, Livingston G, Rantell K, et al. Diagnostic rates and treatment of dementia before and after launch of a national dementia policy: an observational study using English national databases. BMJ Open 2014;4:e004119.

46. Hughes CM, Lapane KL, Mor V, et al. The impact of legislation on psychotropic drug use in nursing homes: a cross-national perspective. J Am Geriatr Soc 2000;48:931–7.

47. Lindesay J, Matthews R, Jagger C. Factors associated with antipsychotic drug use in residential care: changes between 1990 and 1997. Int J Geriatr Psychiatry 2003;18:511–19.

48. Ballard C, Liu M, Theodoulou M, et al. A randomised, blinded, placebo-controlled trial in dementia patients continuing or stopping neuroleptics (the DART-AD trial). PLoS Med 2008;5:e76.

49. Backhouse T, Killett A, Penhale B, et al. Behavioural and psychological symptoms of dementia and their management in care homes within the East of England: a postal survey. Aging Ment Health 2014;18:187–93.

50. Gambassi G, Landi F, Peng L, et al. Validity of diagnostic and drug data in standardized nursing home resident assessments: potential for geriatric pharmacoeconomics. SAGE Study Group. Systematic Assessment of Geriatric drug use via Epidemiology. Med Care 1998;36:167–79.

51. American Society of Consultant Pharmacists. Antipsychotic Medication Use in Nursing Facility Residents. Online Survey Certification and Reporting database, 2011.

52. Hagen B, Esther CA, Iliuta R, et al. Antipsychotic drug use in Canadian long-term care facilities: prevalence, and patterns following resident relocation. Int Psychogeriatr 2005;17:179–93.

53. Almen HM, Finne-Soveri H, Nora A, et al. Use of antipsychotic medications among elderly residents in long-term institutional care: a three-year follow-up. Int J Geriatr Psychiatry 2006;21:286–95.

54. Hien Le TT, Cumming RG, Cameron ID, et al. Atypical antipsychotic medications and risk of falls in residents of aged care facilities. J Am Geriatr Soc 2005;53:1290–5.

55. American Society of Consultant Pharmacists. Policy Statement: Use of Antipsychotic Medications in Nursing Facility Residents. 2012. https://www.ascp.com/sites/default/files/ASCP-antipsychotics-statement.pdf

56. British Geriatrics Society Joint Working Party Inquiry. A Quest for Quality. An Inquiry into the Quality of Healthcare Support for Older People in Care Homes: A Call for Leadership, Partnership and Improvement. 2011. http://www.bgs.org.uk/index.php?option=com_content&Contentid=1484&Itemid=719

57. Black W, Almeida OP. A systematic review of the association between the behavioral and psychological symptoms of dementia and care burden. J Am Geriatr Soc 2008;56:1401–9.

58. Zuidema SU, de Jonghe JF, Verheij FR, et al. Psychotropic drug prescription in nursing home patients with dementia: influence of environmental correlates and staff distress on physicians’ prescription behavior. Int Psychogeriatr 2011;23:1632–9.

59. Bird M, Monger-Cooper I, et al. An integrated approach to intervention: In: Woods B, Clare L, eds. Handbook of the clinical psychology of ageing. Wiley, 2008:571–94.

60. Sorensen L, Foldsang A, Gulmann NC, et al. Determinants for the use of psychotropics among nursing home residents. Int J Geriatr Psychiatry 2001;16:147–54.

61. Wild D, Szczepura A, Nelson S. Residential care home workforce development: The rhetoric and reality of meeting older residents’ future care needs. Joseph Rowntree Foundation 2010. http://www.jrf.org.uk/publications/care-workforce-development.

62. Rochon PA, Stukel TA, Bronskill SE, et al. Variation in nursing home antipsychotic prescribing rates. Arch Intern Med 2007;167:676–83.

63. Svarstad BL, Mount JK, Bigelow W. Variations in the treatment culture of nursing homes and responses to regulations to reduce drug use. Psychiarr Serv 2001;52:666–72.

64. Hughes CM, Donnelly A, Moyes SA, et al. “The way we do things around here”: an international comparison of treatment culture in nursing homes. J Am Med Dir Assoc 2012;13:360–7.

65. Huybrechts KF, Spiegelhalter D, et al. Variation in antipsychotic treatment choice across US nursing homes. J Clin Psychopharmacol 2012;32:11–7.

66. Tjia J, Gurwitz JH, Briesacher BA. Challenge of changing nursing home prescribing culture. Am J Geriatr Pharmacother 2008;6:149–58.

67. Hughes CM, Lapane KL, Mor V. Influence of facility characteristics on use of antipsychotic medications in nursing homes. Med Care 2000;38:1164–73.

68. Szczepura A, Nelson S, Wild D. Models for providing improved care in residential care homes: a thematic literature review. JRF Findings. York: Joseph Rowntree Foundation, 2008.

69. Frank L, Kleinman L, Ciesla G, et al. The effect of risperidone on behaviour in dementia: a three-year follow-up. Int Psychogeriatr 2005;17:169–79.

70. Banerjee S, Hellier J, Romeo R, et al. Study of the use of antidepressants for depression in dementia: the HTA-SADD trial—a multicentre, randomised, double-blind, placebo-controlled trial of the clinical effectiveness and cost-effectiveness of sertraline and mirtazapine. Health Technol Assess 2013;17:1–166.

71. Care Quality Commission. The essential standards. 2014. http://www.cqc.org.uk/content/regulations-service-providers-and-managers

72. Laing & Buisson. Calculating the cost of efficient care homes. York: Joseph Rowntree Foundation, 2008.

73. Kruse CS, Mileski M, Aylaytsev V, et al. Adoption factors associated with electronic health record among long-term care facilities: a three-year follow-up. J Gerontol A Biol Sci Med Sci 2014;69:104–10.

74. National Audit Office. Improving services and support for people with dementia. London: National Audit Office, 2007.

75. Department of Health. National service framework for older people. London: Department of Health, 2001.